FDA challenges stem cell companies, patients run out of time

February 5, 2013
b fac dc z
Neural stem cell. (Credit: Joseph Elsbernd/Flickr)
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The following is an excerpt.

Americans seeking stem cell replacement therapy hope the process can heal them of myriad diseases, and a 2011 report by the Baker Institute estimated the industry could bring in $16 billion in revenue by 2020.

But the Food and Drug Administration has expressed concerns. The agency sued to stop treatments at a Regenerative Sciences clinic in Colorado and closed the labof another company, Celltex Therapeutics, in Texas.

While patients in dire situations are willing to try the therapy (and pay the hefty costs), there’s concern the research doesn’t support broad practice just yet.

Read the full article here: FDA Challenges Stem Cell Companies As Patients Run Out Of Time

Additional Reading:

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

Advertisements
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend